Aliceblue ANT
Aliceblue ANTInstall and trade smarter everywhere
S

Star Imaging and Path Lab Ltd

Complete IPO details, including price band, financials, subscription status, and key insights.

Participate in the Star Imaging and Path Lab Ltd IPO with full transparency. Review issue details, company fundamentals, and financial performance, and apply securely through Alice Blue.

IPO Snapshot

Key metrics and details at a glance.

Price Band

₹142

Per Share

Lot Size

1000 Shares

Minimum Investment

₹1,42,000

Issue Size

₹69.46 Cr

Face Value

₹10

Per Share

IPO Type

Book Building - SME

Retail Quota

35.05%

QIB Quota

49.88%

NII Quota

15.07%

IPO Timeline

Important dates for your applying strategy.

IPO Opens8 Aug
IPO Closes12 Aug
Basis of Allotment13 Aug
Refund Initiation13 Aug
Shares Credited14 Aug
Listing Date18 Aug
IPO Process Completed

Subscription Status

Live demand across investor categories.

Track real-time subscription levels:

*Real-time data subject to exchange updates

Qualified Institutional Buyers (QIB)12.85x
Non-Institutional Investors (NII)5.11x
Retail Individual Investors (RII)2.31x
Overall Subscription3.70x

Star Imaging and Path Lab Ltd

Business model, operations, and market positioning.

Promoter Holding (Pre-Issue)

100%

Promoter Holding (Post-Issue)

71.92%

Issue Type

Book Building - SME

ISIN

INE0YG001013

About the Company

The company operates a diagnostic testing network, NABL accredited, delivering pathology, radiology, Cardiology, and Neurology services in Delhi (B2C, B2B & B2G model), Uttar Pradesh (B2G model), and Nasik (B2G Model) regions of India.

Industry Overview

Global growth is projected at 3.3 percent both in 2025 and 2026, below the historical (2000-19) average of 3.7 percent. The forecast for 2025 is broadly unchanged from that in the October 2024 World Economic Outlook (WEO), primarily on account of an upward revision in the United States offsetting downward revisions in other major economies. Global headline inflation is expected to decline to 4.2 percent in 2025 and to 3.5 percent in 2026, converging back to target earlier in advanced economies than in emerging market and developing economies. Medium-term risks to the baseline are tilted to the downside, while the near-term outlook is characterized by divergent risks. Upside risks could lift already-robust growth in the United States in the short run, whereas risks in other countries are on the downside amid elevated policy uncertainty. Policy-generated disruptions to the ongoing disinflation process could interrupt the pivot to easing monetary policy, with implications for fiscal sustainability and financial stability. Managing these risks requires a keen policy focus on balancing trade-offs between inflation and real activity, rebuilding buffers, and lifting medium-term growth prospects through stepped-up structural reforms as well as stronger multilateral rules and cooperation. Forces Shaping the Outlook: The global economy is holding steady, although the degree of grip varies widely across countries. Global GDP growth in the third quarter of 2024 was 0.1 percentage point below that predicted in the October 2024 WEO, after disappointing data releases in some Asian and European economies. Growth in China, at 4.7 percent in year-over-year terms, was below expectations. Faster-than-expected net export growth only partly offset a faster-than-expected slowdown in consumption amid delayed stabilization in the property market and persistently low consumer confidence. Growth in India also slowed more than expected, led by a sharper-than-expected deceleration in industrial activity. Growth continued to be subdued in the euro area (with Germany's performance lagging that of other euro area countries), largely reflecting continued weakness in manufacturing and goods exports even as consumption picked up in line with the recovery in real incomes. In Japan, output contracted mildly owing to temporary supply disruptions. By contrast, momentum in the United States remained robust, with the economy expanding at a rate of 2.7 percent in year-over-year terms in the third quarter, powered by strong consumption. Global disinflation continues, but there are signs that progress is stalling in some countries and that elevated inflation is persistent in a few cases. The global median of sequential core inflation has been just slightly above 2 percent for the past few months. Nominal wage growth is showing signs of moderation, alongside indications of continuing normalization in labor markets. Although core goods price inflation has fallen back to or below trend, services price inflation is still running above pre-COVID-19 averages in many economies, most notably the United States and the euro area. Pockets of elevated inflation, reflecting a range of idiosyncratic factors, also persist in some emerging market and developing economies in Europe and Latin America. Where inflation is proving moresticky, central banks are moving more cautiously in the easing cycle while keeping a close eye on activity and labor market indicators as well as exchange rate movements. A few central banks are raising rates, marking a point of divergence in monetary policy. Global financial conditions remain largely accommodative, again with some differentiation across jurisdictions (see Box 1). Equities in advanced economies have rallied on expectations of more business friendly policies in the United States. In emerging market and developing economies, equity valuations have been more subdued, and a broad-based strengthening of the US dollar, driven primarily by expectations of new tariffs and higher interest rates in the United States, has kept financial conditions tighter. Economic policy uncertainty has increased sharply, especially on the trade and fiscal fronts, with some differentiation across countries (Figure 1). Expectations of policy shifts under newly elected governments in 2024 have shaped financial market pricing in recent months. Bouts of political instability in some Asian and European countries have rattled markets and injected additional uncertainty regarding stalled progress on fiscal and structural policies. Geopolitical tensions, including those in the Middle East, and global trade frictions remain elevated.

Company History

Our Company was originally incorporated as a private limited company under the Companies Act, 1956 in the name and style of "Star Imaging & Path Lab Private Limited" bearing Corporate Identification Number U85110DL2004PTC126679 dated May 31, 2004, issued by the Registrar of Companies, National Capital Territory of Delhi and Haryana. Subsequently, our Company was converted into a Public Limited Company vide Special Resolution passed by the Shareholders at the Extra-Ordinary General Meeting, held on April 12, 2024, and consequently the name of our Company was changed from "Star Imaging and Path Lab Private Limited" to "Star Imaging and Path Lab Limited" vide a fresh certificate of incorporation dated September 17, 2024 issued by the Registrar of Companies, Central Processing Centre bearing CIN U85110DL2004PLC126679.

Products & Services

  • The company operates a diagnostic testing network, NABL accredited, delivering pathology, radiology, Cardiology, and Neurology services in Delhi (B2C, B2B & B2G model), Uttar Pradesh (B2G model), and Nasik (B2G Model) regions of India.

Growth Strategy

  • Continue to expand presence across India.
  • Expand our offering of diagnostic services with a focus on specialized diagnostics.

Customer Base

Wholesaler and Retailer

Financial Performance

Revenue, profit after tax and total assets across the last 3 reported financial years.

Consolidated figures
Financial Performance Categories

Revenue

+42.7%vs FY23

Amount in ₹ crore

58.5
78.8
83.5
FY23FY24FY25

Profit After Tax (PAT)

+2647%vs FY23

Amount in ₹ crore

0.58
12.4
15.9
FY23FY24FY25

Total Assets

+59.9%vs FY23

Amount in ₹ crore

61.4
81.8
98.2
FY23FY24FY25

Figures in ₹ crore, on a consolidated basis, as reported for FY23 to FY25.

Objects of the Issue

How the company plans to utilize IPO proceeds.

Use of Proceeds

The funds raised through this IPO will be used for:

Initial public offer of 48,92,000 equity shares of face value of Rs. 10/- each of Star Imaging and Path Lab Limited ("Star" or the "Company" or the "Issuer") for cash at a price of Rs.142/- per equity share including a share premium of Rs.132/- per equity share (the "Issue Price") aggregating to Rs. 69.47 crores ("the Offer"), comprising a fresh offer of 39,20,000 equity shares of face value of Rs. 10/- each for cash at a price of Rs. 142/- per equity share including a share premium of Rs. 132/- per equity share aggregating up to Rs. 55.66 crores by the company ("Fresh Offer") and an offer for sale of 9,72000 equity shares of face value of Rs. 10/- each for cash at a price of Rs. 142/- per equity share including a share premium of Rs. 132/- per equity share ("Offered Shares") aggregating up to Rs. 13.80 crores by Pawan Gupta (Selling Shareholder). Out of the offer, 4,80,000 equity shares of face value of Rs. 10/- each for cash at a price of Rs. 142/- per equity share including a share premium of Rs. 132/- per equity share aggregating to Rs. 6.82 crores will be reserved for subscription by market maker to (the "Market Maker Reservation Portion"). This issue includes a reservation of 52,000 equity shares aggregating to Rs. 7.38 crores (Constituting 0.299% of the post issue paid-up equity share capital of the company) for subscription by eligible employees (the "Employee Reservation Portion"). The offer less the market maker reservation portion and eligible employees i.e. Net offer of 43,60,000 equity shares of face value of Rs. 10/- each at a price of Rs. 142/- per equity share including a share premium of Rs. 132/- per equity share aggregating to Rs.61.91 crores is herein after referred to as the "Net Offer". The offer and the net offer will constitute 28.083% and 25.029% respectively, of the post issue paid up equity share capital of the company.

*Subject to approvals and market conditions.

Strengths & Risks

Key competitive advantages and factors to consider before investing.

Strengths and Risk Factors
  • Integrated diagnostics provider with one-stop solution offering pathology and radiology services.
  • Established presence and proven track record.
  • Dedicated management team with significant industry experience.
  • The Company, Promoter and Directors are parties to certain legal proceedings. Any adverse decision in such proceedings may have a material adverse effect on its business, results of operations and financial condition.
  • There have been instances in the past where the company has not made regulatory filing of Consolidated Financials of the Company with RoC.
  • The Company has reported certain negative cash flows from its operating activity, investing activity and financing activity, details of which are given below.
  • The Company has not fulfilled its CSR obligation u/s 135 of the Companies Act, 2013 for the F.Y. 2021-22 to F.Y. 2023-24. Such noncompliance/ default may attract penalties on the Company and its Directors.
  • Form-2 for Return of Allotment filed with the Registrar of Companies for the period April 28, 2011 is not traceable.

Frequently Asked Questions

01

What is the minimum investment required to apply for this IPO?

The minimum investment depends on the lot size and the upper price band of the issue. Investors must apply for at least one lot, and the total investment amount is calculated by multiplying the lot size by the upper price band.
02

How is IPO allotment decided?

IPO allotment is determined based on demand and SEBI guidelines. If the IPO is oversubscribed in the retail category, allotment is typically done through a computerized lottery system to ensure fair distribution among eligible applicants.
03

When will I know if shares are allotted to me?

Allotment status is usually finalized a few days after the IPO closes. Once finalized, shares are either credited to your Demat account (if allotted) or the blocked funds are released back to your bank account.
04

Can I modify or cancel my IPO application?

Yes, you can modify or cancel your IPO application anytime before the IPO closing date. Changes can be made through your Alice Blue account, subject to exchange cut-off timings.
05

What happens if the IPO is oversubscribed?

If the IPO receives more applications than the number of shares available, it is considered oversubscribed. In such cases, allotment in the retail category is done on a proportionate or lottery basis, and not all applicants may receive shares.
Star Imaging and Path Lab Ltd IPO Status, GMP, Price & Dates Today | Alice Blue